Clinical trial of sertraline in the treatment of night eating syndrome

Authors


Abstract

Objective

To test the efficacy of sertraline in the treatment of night eating syndrome.

Methods

Seventeen patients meeting criteria for night eating syndrome received sertraline in a 12-week open-label, nonblinded trial. Outcome was assessed by four primary measures, namely, the number of nocturnal awakenings, the number of ingestions, total daily caloric intake after the evening meal, and an overall rating of change from the Clinical Global Impression of Improvement scale (CGI-I).

Results and Discussion

An intent-to-treat analysis revealed highly significant improvements across all four primary outcome measures for all 17 subjects. Five subjects achieved full remission of symptoms (CGI-I score of 1 = very much improved) and lost a significant amount of weight over the course of the study (−4.8 ± 2.6kg, p < .05). Sertraline, a selective serotonin reuptake inhibitor, may be beneficial in the treatment of night eating syndrome. © 2003 by Wiley Periodicals, Inc. Int J Eat Disord 35: 16–26, 2004.

Ancillary